Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real‐world setting
American Journal of Hematology | August 1, 2022 | Volume: 97 | Issue: 10 | Pages: No page available
10.1002/ajh.26672
| PMID 35959963